The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, ...

It hasn't been the best quarter for Scancell Holdings plc (LON:SCLP) shareholders, since the share price has fallen 21% in that time. But in three years the returns have been great. In three years the ...

UK biotech Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine. The SCOPE study of iSCIB1+, an ...

Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as ...

Scancell Holdings (GB:SCLP) has released an update. Scancell Holdings has announced that all resolutions at its recent Annual General Meeting have been successfully passed, paving the way for further ...

(RTTNews) - Scancell Holding plc (SCLP) announced that the U.S FDA has cleared its Investigational New Drug Application for a global Phase 3 trial evaluating iSCIB1+ in advanced melanoma. Melanoma ...

First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer First-in-human clinical trial in patients with triple negative ...

U.K. biotech Scancell is taking no chances when it comes to carrying out trials of its candidate vaccine for non-small cell lung cancer (NSCLC). The company has joined forces with the Addario Lung ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

Scancell to host presentation and Q&A on data at 13:00 BST NOTTINGHAM, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® ...

It is hoped that the vaccine will generate protection not only against SARS-CoV-2, but also against new strains of coronavirus that may arise in the future Scancell Holdings has secured funding of ...